Can a dietary supplement providing natural cGP (cyclic Glycine-Proline) compliment the body’s own internal levels of cGP and help improve the metabolic health of type 2 diabetes sufferers and aid in the recovery of complications associated with metabolic syndrome

ISRCTN ISRCTN84351085
DOI https://doi.org/10.1186/ISRCTN84351085
EudraCT/CTIS number Nil Known
Secondary identifying numbers MR-42-23-028752
Submission date
25/07/2024
Registration date
29/07/2024
Last edited
30/07/2024
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nutritional, Metabolic, Endocrine
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English Summary

Background and study aims
Metabolic syndrome is a cluster of clinical manifestations including type-2 diabetes mellitus (T2DM), hypertension and dyslipidemia. Elevated blood glucose and insulin levels damage capillary networks and cause diabetic peripheral neuropathy, hypertension and other complications due to loss of microcirculation. With no cure, the prognosis of peripheral neuropathy is poor and a major cause of limb amputation. The 5-year survival rate after limb amputation is about 2 years, shorter than colon, breast and prostate cancers. Cyclic glycine-proline (cGP) is a trophic molecule that keeps the function of insulin-like growth factor-1 (IGF-1) normal. The key function of IGF-1 is to maintain the network of small blood vessels and capillaries. Thus, we hypothesize that the administration of natural cGP, via an orally bioavailable dietary supplement, may improve foot sensation, blood pressure and glucose metabolism by supporting a healthy microcirculation.

Who can participate?
Male and females aged between 45 and 80 years with medical histories of T2DM, hypertension and foot peripheral neuropathy can volunteer to participate in the trial.

What does the study involve?
One group will take one capsule/day providing 20 - 25µg natural cGP (low dose) and the other group taking one capsule/day delivering 40 - 45µg natural cGP (high dose). The capsules are formulated using natural food ingredients sourced from New Zealand and encapsulated in a GMP facility. Three hospital visits are planned over a 6-month trial period. At each hospital visit foot sensation is to be assessed using Semmes-Weinstein monofilament, vibration and warm/cold perception threshold tests. These tests are the routine practice for assessing feet' sensory function. Fasting blood samples (10ml) are to be collected, and blood pressure is measured during each hospital visit. Participants are instructed to remain on their medications for hypertension, hyperlipidemia, and diabetes and to maintain their current lifestyle throughout the trial.

What are the possible benefits and risks of participating?
Our body naturally produces cGP keeping the function of IGF-1 normal. When our own cGP production is insufficient we experience metabolic dysfunction. Oral supplementation with a physiological dose of natural cGP designed to top up the shortage of our own cGP would be beneficial and have minimal interaction with the medications that the participants are using.

Where is the study run from?
This study will be conducted at the Department of Endocrinology, Tianyou Hospital, Wuhan University of Science and Technology, China.

When is the study starting and how long is it expected to run for?
May 2020 to May 2023

Who is funding the study?
The study is co-funded by The Health Commission, Hubei, China, and The cGP Lab Ltd., New Zealand.

Who is the main contact?
Dr J Guan, Jian.guan@thecgplab.com

Contact information

Dr Jian Guan
Public, Scientific, Principal Investigator

300 Richmond Road, Grey Lynn
Auckland
1021
New Zealand

ORCiD logoORCID ID 0000-0002-2847-1627
Phone +64 0210366863
Email jian.guan@thecgplab.com

Study information

Study designTwo-armed open-label study
Primary study designInterventional
Secondary study designNon randomised study
Study setting(s)Hospital
Study typePrevention, Treatment, Efficacy
Participant information sheet Not available in web format, please use the contact details to request a patient information sheet.
Scientific titleAn observational study suggested a cause-effect relationship between plasma cGP and clinical manifestations of Type 2 diabetes mellitus (T2DM) and its associated vascular complications. To confirm such relationship, this open label trial is designed to examine the efficacy of natural cGP supplementation on manifestations of T2DM.
Study hypothesisAs a natural reaction, endogenous cGP (cyclic glycine-proline) increases, however, the response is insufficient to address metabolic disorders and vascular complications. This leads us to hypothesise that further increasing plasma cGP via oral administration of natural cGP may improve clinical outcomes of metabolic syndrome.
Ethics approval(s)

Approved 01/05/2020, The Ethics Committee of Tianyou Hospital, Affiliated to Wuhan University of Science & Technology (Tianyou Hospital, 9 Tujialing, Wuchang, Wuhan, 430064, China; +8613554623321; yangyang1003@wust.edu.cn), ref: Approval number: 2021-02-28; Revised approval number LL2024-02-08-01

ConditionThe efficacy of cGP in vascular complications in patients with diabetes
InterventionTo confirm the cause-effect relationship of cyclic glycine-proline (cGP) to manifestations of type 2 diabetes (T2DM), an open-label study is used to examine the efficacy of natural cGP supplementation on manifestations of T2DM.

The two-armed open-label trial is to be conducted at the Tianyou Hospital, Wuhan University of Science and Technology, China. Thirty-eight T2DM participants with foot sensory deficits will be allocated into 2 cohorts and receive either 20 - 25µg or 40 - 45µg natural cGP daily. There will be three hospital visits during a 6-month trial. Foot sensation is to be assessed using Semmes-Weinstein monofilament, vibration and warm/cold perception threshold tests. Blood pressure measured. Fasting blood samples will be collected.
Intervention typeSupplement
Primary outcome measureFoot sensation measured using Semmes-Weinstein monofilament, vibration and warm/cold perception threshold tests at three hospital visits (Before supplementation, after 3 months of supplementation, and after 6 months of supplementation)
Secondary outcome measuresMeasured before supplementation, after 3 months of supplementation, and after 6 months of supplementation:
1. Systolic and diastolic blood pressure measured using a sphygmomanometer at three hospital visits
2. Glucose intolerance measured using fasting blood glucose, HBA1c (%), and triglyceride/glucose index at three hospital visits
Overall study start date01/05/2020
Overall study end date01/05/2023

Eligibility

Participant type(s)Healthy volunteer, Patient
Age groupMixed
Lower age limit45 Years
Upper age limit80 Years
SexBoth
Target number of participants40
Total final enrolment38
Participant inclusion criteria1. Male and female participants aged between 45 and 80 years old
2. More than 8 years of medical history of Type 2 Diabetes Mellitus (T2DM)
3. Current diagnosis of foot diabetic peripheral neuropathy (DPN)
4. Diagnosis of T2DM based on:
4.1. Fasting glucose ≥ 7 mmol/L and/or
4.2. HbA1c ≥ 6.5%
5. Diagnosis of foot DPN based on:
5.1. Self-reporting symptoms
5.2. Foot sensory testing scores
6. Inclusion criteria are independent of:
6.1. Body Mass Index (BMI)
6.2. Blood pressure
6.3. Plasma lipid profiles
6.4. Other complications of T2DM
Participant exclusion criteria1. Type 1 diabetes
2. Diabetic foot ulcers
3. Any other cause of peripheral neuropathy (drug or injury or Covid-19 associated peripheral neuropathy)
4. Medical history of degenerative neurological conditions
5. History of cognitive impairment
6. Major mental health issues such as:
6.1. Schizophrenia
6.2. Severe depression
6.3. Anxiety
Recruitment start date01/05/2021
Recruitment end date01/05/2023

Locations

Countries of recruitment

  • China

Study participating centre

Tianyou Hospital, The Wuhan University of Sciences and Technology
9 Tujialing, Wuchang
Wuhan
430064
China

Sponsor information

The cGP Lab
Industry

300 Richmond Road, Grey Lynn
Auckland
1021
New Zealand

Phone +64 21986022
Email amanda.wiggins@thecgplab.com
Website https://cgpmax.com/
Wuhan University of Science and Technology
University/education

Tianyou Hospital
Wuhan
43008
China

Phone +64 13554623321
Email yangyang1003@wust.edu.cn
Website http://www.wust.edu.cn/default.html
ROR logo "ROR" https://ror.org/00e4hrk88

Funders

Funder type

Industry

The cGP Lab Ltd

No information available

Health Commission of Hubei Province
Government organisation / Local government
Alternative name(s)
Hubei Provincial Health Commission, 湖北省卫生健康委员会
Location
China

Results and Publications

Intention to publish date01/05/2025
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request, Published as a supplement to the results publication
Publication and dissemination planPlanned publication in a peer-reviewed journal
IPD sharing planThe datasets generated during and/or analysed during the current study will be available upon request from Jian Guan, jian.guan@thecgplab.com
The datasets generated and/or analysed during the current study will be published as a supplement to the results publication

• The type of data that will be shared
Raw data that collected during the trial without any personal information of participants.

• Timing for availability
After the main data being published.

• Whether consent from participants was required and obtained
Yes

• Comments on data anonymization
The data will be shared without private information being divulged. The individual participant data were collected and recorded in Chinese.

Editorial Notes

30/07/2024: Internal review.
29/07/2024: Trial's existence confirmed by Tianyou Hospital.